Eton Pharma Q2 FY26 EPS swings to GAAP profit of $0.35; revenue more than doubled to $37.6 million
ETON•Q2 revenue and earnings improve sharply
Eton Pharmaceuticals posted Q2 2026 revenue of $37.6 million, more than doubled from a year earlier on portfolio growth.
Net income swung to $11.6 million, with GAAP diluted EPS at $0.35.
Adjusted EBITDA rose to $16.2 million, lifting the adjusted EBITDA margin to 43% of revenue.
Full-year outlook raised and product updates
The company raised its 2026 revenue outlook to exceed $145 million, with an adjusted EBITDA margin target raised to at least 35%.
HEMANGEOL relaunched May 1; about 95% of existing patients transitioned by end-June, with ASN-001 licensed for a potential 2027 NDA.
